Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China · Delayed Price · Currency is CNY 11.56
+0.01 (0.09%)
Apr 30, 2026, 3:04 PM CST
SHE:002900 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | -319.78 | -341.57 | 58.68 | 73.66 | 30.21 | 350.95 |
Depreciation & Amortization | 142.69 | 142.69 | 111.07 | 108.68 | 106.57 | 99.13 |
Other Amortization | 5.72 | 5.72 | 5.6 | 5.35 | 3.78 | 4.02 |
Loss (Gain) From Sale of Assets | 0.52 | 0.52 | -0.19 | 2.61 | 13.31 | 1.92 |
Asset Writedown & Restructuring Costs | 82.07 | 82.07 | 1.31 | -0.82 | 2.91 | -0.69 |
Loss (Gain) From Sale of Investments | -21.53 | -21.53 | -17.78 | -56.11 | -59.83 | -593.2 |
Provision & Write-off of Bad Debts | - | - | 1.22 | -2.86 | 0.59 | 1.8 |
Other Operating Activities | -68.6 | 23.28 | 27.34 | 1.51 | -2.38 | 16.1 |
Change in Accounts Receivable | 174.91 | 174.91 | -135.48 | -6.74 | -10.03 | 49.61 |
Change in Inventory | 31.74 | 31.74 | -98.88 | -46.8 | 0.62 | 26.49 |
Change in Accounts Payable | -122.44 | -122.44 | 76.7 | -51.42 | 47.19 | -63.69 |
Operating Cash Flow | -106.34 | -36.25 | 30.69 | 35.69 | 144.64 | -12.53 |
Operating Cash Flow Growth | - | - | -14.02% | -75.32% | - | - |
Capital Expenditures | -202.49 | -247.73 | -346.21 | -299.58 | -89.22 | -73.95 |
Sale of Property, Plant & Equipment | 0.68 | 0.54 | 0.03 | 0.22 | 0.27 | 11.61 |
Cash Acquisitions | - | - | - | -15.98 | - | - |
Divestitures | - | - | - | - | - | -4.05 |
Investment in Securities | -60 | -114 | -6.08 | 46.69 | 500 | -227.73 |
Other Investing Activities | 20.38 | 29.14 | 20.85 | 8.12 | 8.21 | 15.89 |
Investing Cash Flow | -241.43 | -332.04 | -331.41 | -260.52 | 419.25 | -278.23 |
Long-Term Debt Issued | - | 1,058 | 859.55 | 280 | 431 | 471.6 |
Total Debt Issued | 867.74 | 1,058 | 859.55 | 280 | 431 | 471.6 |
Long-Term Debt Repaid | - | -898.85 | -643.77 | -242.47 | -274.74 | -282.46 |
Total Debt Repaid | -721.69 | -898.85 | -643.77 | -242.47 | -274.74 | -282.46 |
Net Debt Issued (Repaid) | 146.05 | 159.42 | 215.77 | 37.53 | 156.26 | 189.14 |
Repurchase of Common Stock | - | - | -0.22 | -1.17 | - | - |
Common Dividends Paid | -93.84 | -110.28 | -104.56 | -41.04 | -109.34 | -34.31 |
Other Financing Activities | 2.42 | 206.17 | 202.85 | -10.41 | -154.04 | -198.53 |
Financing Cash Flow | 54.63 | 255.3 | 313.85 | -15.08 | -107.12 | -43.71 |
Net Cash Flow | -293.14 | -113 | 13.12 | -239.91 | 456.77 | -334.48 |
Free Cash Flow | -308.83 | -283.98 | -315.52 | -263.89 | 55.42 | -86.48 |
Free Cash Flow Margin | -37.97% | -35.97% | -27.86% | -22.23% | 5.39% | -9.14% |
Free Cash Flow Per Share | -0.95 | -0.90 | -1.02 | -0.86 | 0.18 | -0.28 |
Cash Income Tax Paid | 33.2 | 37.47 | 42.26 | 92.12 | 85.85 | 74.74 |
Levered Free Cash Flow | -192.4 | -184.09 | -366.52 | -243.03 | 83.23 | -28.2 |
Unlevered Free Cash Flow | -192.4 | -184.09 | -347.16 | -228.72 | 97.37 | -19.57 |
Change in Working Capital | 72.56 | 72.56 | -156.54 | -96.32 | 49.49 | 107.42 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.